Hypertriglyceridemia is a condition characterized by elevated triglyceride levels in the blood, increasing the risk of cardiovascular diseases and pancreatitis. It accounts for around 4% to 10% of all acute pancreatitis cases globally. There is a high unmet clinical need for better therapies, as current treatment options, such as fibrates and omega-3 fatty acids, have limitations. The growing focus on novel hypertriglyceridemia therapeutics, including APOC3 and ANGPTL3 inhibitors, is likely to drive pipeline growth in the coming years.
Major companies involved in the hypertriglyceridemia pipeline drugs market include OrsoBio, Inc., Ionis Pharmaceuticals, Inc., and others.
Leading drugs currently in the pipeline include Plozasiran Injection, DR10624 Injection, Kylo-12, and others.
The rising advancements in gene-based treatments, targeted biologics, and increasing research on APOC3 and ANGPTL3 inhibitors are driving the growth of the hypertriglyceridemia drug pipeline.
The Hypertriglyceridemia Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into hypertriglyceridemia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hypertriglyceridemia. The hypertriglyceridemia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hypertriglyceridemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hypertriglyceridemia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hypertriglyceridemia.
Hypertriglyceridemia is a condition characterized by abnormally high triglyceride levels in the blood, increasing the risk of cardiovascular disease and acute pancreatitis. It occurs due to genetic factors, obesity, diabetes, excessive alcohol intake, and a high-fat diet. Insulin resistance and metabolic disorders can also contribute to hypertriglyceridemia by impairing lipid metabolism, leading to excessive triglyceride accumulation in the bloodstream.
Hypertriglyceridemia treatment includes lifestyle modifications such as a low-fat diet, regular exercise, and weight management. Medications like fibrates, omega-3 fatty acids, and statins help lower triglyceride levels. Emerging drug candidates offer promising therapeutic potential. Advancements in gene-based and targeted therapies continue to improve hypertriglyceridemia management and patient outcomes.
Hypertriglyceridemia accounts for 4% to 10% of all acute pancreatitis (AP) cases globally. In the United States, 26.8 million adults have moderate hypertriglyceridemia (200–499 mg/dL), while 2.3 million have severe hypertriglyceridemia (≥500 mg/dL. Severe hypertriglyceridemia is associated with central obesity (70.3%), diabetes (32.7%), and chronic kidney disease (21.6%). In the United Kingdom, familial hypertriglyceridemia affects approximately 1% of the population.
This section of the report covers the analysis of hypertriglyceridemia drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total hypertriglyceridemia clinical trials.
The drug molecule categories covered under the hypertriglyceridemia pipeline analysis include small molecules, monoclonal antibodies, gene therapies, RNA-based therapies, and peptides. The hypertriglyceridemia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hypertriglyceridemia.
The EMR report for the hypertriglyceridemia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hypertriglyceridemia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hypertriglyceridemia clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hypertriglyceridemia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hypertriglyceridemia drug candidates.
Plozasiran (ARO-APOC3) is being evaluated in a Phase III study sponsored by Arrowhead Pharmaceuticals. The study is assessing the safety and efficacy of Plozasiran in adults with hypertriglyceridemia. It is expected to be completed by October 2026, it will enroll approximately 1,328 participants receiving either Plozasiran or a placebo.
The DR10624 drug candidate is being evaluated in a Phase II clinical trial sponsored by Zhejiang Doer Biologics Co., Ltd. The study is designed to assess the efficacy and safety of DR10624 in patients with severe hypertriglyceridemia (SHTG). The trial will focus on how effectively DR10624 manages triglyceride levels and its safety profile in individuals with this condition. With an estimated enrollment of 72 participants, the trial is expected to conclude by October 2025.
Kylo-12 is currently being evaluated in a Phase 1 clinical study for hypertriglyceridemia. The study sponsored by Kylonova (Xiamen) Biopharma Co., Ltd., aims to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. With around 50 participants, the trial is expected to be completed by August 30, 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Hypertriglyceridemia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for hypertriglyceridemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hypertriglyceridemia collaborations, regulatory environments, and potential growth opportunities.
Atherosclerotic Cardiovascular Disease (ASCVD) Drug Pipeline
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share